Humira Market 2030: Biosimilars Reshaping Autoimmune Therapy
The global Humira market was valued at USD 10.34 billion in 2024 and is projected to decline to USD 4.11 billion by 2030, reflecting a CAGR of -11.29% from 2025 to 2030. This decline is primarily driven by the increasing availability of biosimilars following the expiration of Humira's patent protection. Although the global burden of autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease remains high, the market environment is becoming increasingly competitive due to the entry of lower-cost alternatives. Despite ongoing investments in research and development, geographic expansion, and strategic collaborations by pharmaceutical companies, pricing pressures and a shift in patient preferences toward newer biologics continue to impact Humira’s market performance. The proliferation of biosimilars is significantly reshaping the Humira landscape by improving affordability and accessibility. In 2024, the U.S. FDA approved multiple biosimilars including A...